# Cardiac Regenerative Therapy Using Gene-Edited Stem Cells to Improve Transplantation Outcomes

> **NIH NIH R56** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2023 · $400,417

## Abstract

Cardiovascular disease is the leading cause of morbidity and mortality in the United States. A significant loss
of cardiomyocytes from myocardial infarction (MI) can result in progressive deterioration of cardiac function.
Many patients do not recover their cardiac function despite optimal medical therapies and develop progressive
adverse structural and electrical remodeling leading to heart failure (HF) with lethal consequences. HF remains
a deadly clinical syndrome with 5-year mortality of 45–60%. Therefore, there is a compelling need to seek new
options for patients in end-stage HF. Since adult cardiac myocytes are unable to proliferate sufficiently to replace
the damaged tissue, stem cell therapy represents a new promising approach for the treatment of end-stage HF,
since it aims at generating new functional myocardium and inducing neoangiogenesis. However, one of the main
challenges of cardiac stem cell transplantation is the survival and retention of transplanted cells in the hostile
milieu. We have recently published compelling data to demonstrate the one of the main causes of transplanted
stem cell loss is inflammation in a murine post-MI model. Therefore, the overarching goal of this proposal is to
target genes involved in the inflammatory pathway in somatic cells that will be transplanted, to improve
transplantation outcomes in end-stage HF. The proposal addresses the critical role of inflammation induced-cell
death that severely impede cardiac stem cell therapy. Successful completion will pave way to facilitate future
personalized cardiovascular care for patients with end-stage HF and the translation of transplantation therapies
from bench side to clinical practice.

## Key facts

- **NIH application ID:** 10905166
- **Project number:** 1R56HL167932-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** Padmini Sirish
- **Activity code:** R56 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $400,417
- **Award type:** 1
- **Project period:** 2023-09-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10905166

## Citation

> US National Institutes of Health, RePORTER application 10905166, Cardiac Regenerative Therapy Using Gene-Edited Stem Cells to Improve Transplantation Outcomes (1R56HL167932-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10905166. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*